https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=1627
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=1627
No pharmaceutical opinion available for this interaction.
Ritonavir can inhibit the metabolism (CYP 3A4 and 2D6) and increase the plasma concentration of Trazodone.
–
–
–
Possible increase of adverse effects.
If antiretroviral therapy is going on, start with a small dose and gradually increase depending on efficacy and safety.
If patient already on trazodone and antiretroviral therapy is started, reduce the dose by 50% and gradually increase depending on efficacy and safety.
In patients already being treated with this combination and tolerating it, if deemed appropriate, keep actual treatment and exercise close monitoring of adverse effects.
–
Trazodone toxicity: dizziness, fatigue, sweating, orthostatic hypotension, syncope, priapism.
Anticholinergic adverse effects: xerostomia, constipation, urinary retention, sedation, drowsiness, blurred vision, akathisia, convulsions, tachycardia, hypotension, etc.
–
| Reference number |
|---|
| # patients |
| HIV |
| Dose |
| Frequency |
| AUC |
| Cmax |
| Cloral |
| T1/2 |
| Duration (days) |
| 1515 |
|---|
| 10 |
| - |
| 50 mg |
| x 1 |
| + 140% (2.4 x) |
| + 34% |
| - 52% |
| + 120% |
| 1515 |
|---|
| 10 |
| - |
| 200 mg |
| BID |
| 2 |
Ref #1515 : Cases of patients showing symptoms as nausea, dizziness, fatigue, performance issues, hypotension and syncope have been reported.